FINAL PROGRAMME - Chronic Viral Hepatitis Meeting

Alan KAY kay at lyon151.inserm.fr
Sat Sep 20 01:52:45 EST 1997


For information on the accompaning ICN Flavivirus Symposium (Lyon, 9th 
October 1997) and for details of registration at the Chronic Viral Hepatitis 
Meeting, please consult the dedicated web site at :

<http://www.lyon151.inserm.fr/hepatitis97-lyon.html>

The final programme for the Vth International Conference "Current Trends in 
Chronically Evolving Viral Hepatitis" is as follows:

FINAL PROGRAMME

Vth International Conference
Current Trends in Chronically Evolving Viral Hepatitis
10-11th October 1997
PALAIS DES CONGRÈS - LYON

Friday 10 October - Morning
08h15-08h30     Welcome : Christian TRÉPO
Opening : Sheila SCHERLOCK
Evolution of antiviral drugs : is there concordance between discovery and
therapy

08h30-10h30 First Session : Viral kinetics

Patrizia FARCI
The HCV quasispecies : biological and clinical implications

Alan PERELSON
Uncovering the dynamics of HIV and HCV in vivo via mathematical 
modeling

Nancy LAM
HCV kinetics : acute dose response to interferon

Rafael ESTEBAN
European study of induction IFN therapy for chronic HCV

09h15-09h30     DISCUSSION

David GRETCH
HCV mutation during IFN therapy

Jean-Michel PAWLTOSKY
The effect of pretreatment HCV quasispecies mutations on IFN reponse

Patricia PONTISSO (Martina GEROTTO)
HCV kinetics during HCV infections

F.C. BEKKERING
Ultrarapid hepatitis C virus clearance by daily high dose Interferon in
nonresponders to standard therapy.

10h10-10h30     DISCUSSION

10h30-11h00     BREAK

11h00-12h40 Second Session : Viral detection

Guiseppe COLUCCI
Development and clinical applications of quantitative PCR assays
for HCV and HBV viral load determination

Andrew CONRAD
The use of PCR dependant algorithm for he management of patients 
infected with HCV.

Juan I. ESTEBAN
HCV replication. Correlation between HCV RNA and HCV core antigen 
quantitation.

11h30-11h40     DISCUSSION

Cyrille FERAY
Compartimentalisation of HCV genome : a new concept

Francesco NEGRO
Detection of hepatitis C virus RNA by in situ hybridization : a critical
appraisal

Mauro BENDINELLI
Differences in hepatitis C virus quasispecies composition between liver,
peripheral blood mononuclear cells and plasma.

Klaus M. WEINBERGER
Sequence variability of the HBS-gene in chronic carriers of
hepatitis B virus (HBV) lacking serologically detectable HBSAG.

Vincente CARRENO
Hepatotropism of GB-C virus/HCV

12h30-12h40     DISCUSSION

12h40-14h00     LUNCH and POSTER VIEWING

Friday 10 October - Afternoon

14h00-15h50 Third Session : Immune response

Geoffrey DUSHEIKO
Host immune responses in chronic HCV infection

Nicolaï NAOUMOV
Host immune responses in chronic HCV infection.

Gerd PAPE
Association of virus specific helper T-cell response with viral clearance
in acute HCV infection

Barbara REHERMAN
Cytotoxic T-cells in hepatitis C : analysis 20 years after an infection
with one strain of hepatitis C virus.

ZHUZU Zhang
Cross-reactive and genotype specific T cell responses to the hepatitis C
virus in infected humans and immunized mice.

14h50-15h00     DISCUSSION

Michel DOFFOEL
Lymphocyte reacivity to Hepatitis C virus antigens shows evidence for
exposure to hepatitis C virus in HCV-seronegative spouses of HCV-
infected
patients.

Geert MAERTENS
Specific association of immune response to the HCV E1 protein with
hepatitis C disease activity

Guido GERKEN
Mechanisms in the viral host interaction in hepatitis B virus infection

L. LEIFIELD
Costimulatory molecules in fulminant hepatic failure.

15h40-15h50     DISCUSSION

15h50-16h15     BREAK

16h15-18h00 Fourth Session : New approaches for therapy

Alfred PRINCE
Immunotherapy of chronic hepatitis virus infection

ROGGENDORF M.
Strategies for therapeutic vaccination of chronic hepadna virus infection

Christoph SEEGER
Host-virus interactions in HBV replication

Hubert BLUM
Gene therapy for chronical viral hepatitis

17h00-17h15     DISCUSSION

Thierry POYNARD
Natural history of hepatitis C.

Ilkka JULKUNEN
Kinetics and magnitude of Interferon-induced antiviral gene expression in
hepatoma cells

Christine ROLLIER
DNA mediated immunization elicits a protective immune response against
hepadnaviral infection.

Anne FOURNILLIER
Evaluation of HCV E-2 envelope glycoprotein expressing plasmids in the
development of a DNA vaccine.

17h50-18h00     DISCUSSION

18h00-19h00     POSTER VIEWING

Saturday 11 October - Morning

08h15-10h20 Fifth Session : Public health therapy

Miriam ALTER
Prevention and control of hepatitis C with interferon

Alfonso MELE
Prevention of hepatitis C in Italy : lessons from surveillance of type
specific acute viral hepatitis

Jacques DRUCKER
Epidemiology of hepatitis C infection in France

Robert VRANCKS
Hepatitis virus B vaccination results and antenatal transmission of HBV
markers to neonates

09h15-09h40     DISCUSSION

Gloria TALIANI
Ribavirin for the retreatment of HCV + patients non responder to 
Interferon

Lawrence SERFATY
Risk factors and natural history of HCV related cirrhosis

Feruccio BONINO
The impact of HBV infection on the natural history and response to
interferon of chronic hepatitis C patients.

10h10-10h20     DISCUSSION

10h20-10h50     BREAK

10h50-12h45 Sixth Session : Therapy

Christian BRECHOT
Mechanisms of interferon resistance in chronic HCV infection

Antonio CRAXI
The long-term course of IFN-treated patients with chronic hepatitis C

Françoise DEGOS
Renforced versus standard regimen of interferon alfa in chronic hepatitis 
C
infection. Results of a multicentric randomized trial in 244 patients

Howard THOMAS
Overcoming non-response at 3 months of interferon therapy

Graham FOSTER
" HCV treatment " An audit of results of Interferon therapy for HCV in West
London

11h40-11h55     DISCUSSION

Alfredo ALBERTI
Sequential treatment of chronic hepatitis C with interferon and ribavirin

Christian TREPO
Predictors of response to Famciclovir treatment in chronic hepatitis B

Patrick MARCELLIN
Combination therapy in chronic hepatitis B

Stephano HADZYIANNIS
Nucleoside analogue and combination therapy of HBeAg negative chronic
hepatitis B

12h35-12h45     DISCUSSION

12h45-14h00     LUNCH

Saturday 11 October - Afternoon

14h00-15h35 Seventh Session : New viruses and variants

Mario RIZZETTO
An update on HDV infection and hepatitis D

Hélène NORDER
Genetic comparison of GB virus C strains derived worldwide indicates an
extremely low rate of molecular evolution.

Michael MANNS/Dr HERINGLAKE
GBV-C and fulminant hepatic failure

14h30-14h45     DISCUSSION

Hans WILL
Structural and functional complexity of HBV variants

Maria RAPICETTA
Molecular strategies of hepadnavirus "quasispecies" adaptation to a new 
host.

Fabien ZOULIM
Rapid detection of HBe Ag negative variants of HBV : influence of 
mutations
in the promoter and the 1st Aug of the  pre-C region on viral persistence.

HGM NIESTERS
Mutations in the hepatitis B virus polymerase gene during prolonged
lamivudine treatment : indications for the involvement of two mutations.

15h25-15h35     DISCUSSION

15h35-16h00     BREAK

16h00-17h50 Eighth Session : Breakthroughs

Marie-Annick BUENDIA
Evidence for the involvement of two distinct tumor suppressor loci on
chromosome 8p in hepatocellular carcinoma by deletion mapping

Marie-Anne PETIT
Potential hepatocellular receptors for hepatitis B virus

Colin HOWARD
Characterisation of HBV pre-S hepatocyte binding domains and a CD1a-
like cellular receptor using epitope libraries.

Linda ZIGNEGO
HCV-related lymphoproliferative disorders.

16h40-16h50     DISCUSSION

17h00-17h10    

Catharina HULTGREN
Ribavirin therapy shifts the T-Helper 1 (Th1)/Th2 subset balance in vivo.

Jesus PRIETO
Tree-shrews as an in vivo test tube for propagation of HCV infection

Petr. G. DERYABIN
HCV reproduction  in primary cells cultures of suckling mouse brain 
origin"

John VIERLING (with F. ZEYTIN)
Development of model systems in vitro and in vivo

Fusun ZEYTIN
Laboratories without walls : a novel design for creating an Interactive,
Multinational, and Mutlidisciplinary HCV research programme

17h40-17h50     DISCUSSION

17h50-18h00     Jean-Pierre BENHAMOU
                CONCLUSIONS


	

-- 
Alan KAY
INSERM U271
"Virus des hepatites, retrovirus Humains et pathologies associees"
151 cours Albert Thomas, 69424 LYON CEDEX 03, FRANCE
e-mail : kay at lyon151.inserm.fr
tel : (33) 04 72 68 19 76
fax: (33) 04 72 68 19 71




More information about the Bioforum mailing list